Ezt az oldalt automatikusan lefordították, és a fordítás pontossága nem garantált. Kérjük, olvassa el a angol verzió forrásszöveghez.

Super-voltage PRF of Stellate Ganglion Versus Super-voltage PRF of T2 T3 Sympathetic Ganglia in Managing PMPS. (PMPS PRF)

2026. június 23. frissítette: Ahmed Mohamed Soliman, National Cancer Institute, Egypt

Super-voltage Pulsed Radiofrequency of Stellate Ganglion Versus Super-voltage Pulsed Radiofrequency of T2 T3 Sympathetic Ganglia in Managing Postmastectomy Pain Syndrome.

The aim of this study is to compare the effectiveness of super-voltage pulsed radiofrequency of stellate ganglion and super-voltage pulsed radiofrequency of T2-T3 sympathetic ganglia in the treatment of postmastectomy pain syndrome.

A tanulmány áttekintése

Részletes leírás

Rationale for our study:

Supervoltage Pulsed Radiofrequency (SV-PRF) is an advanced neuromodulation technique that delivers higher-voltage short pulses (typically 60-90 V) while keeping tissue temperature below neurodestructive levels (<42°C), allowing deeper electric-field penetration, enhanced C-fiber modulation, and sustained changes in sympathetic outflow without causing structural nerve injury, theoretically providing longer-lasting analgesia and improved safety compared to standard PRF. Among interventional options for sympathetically mediated PMPS, stellate ganglion (SGB) and T2-T3 sympathetic interventions have emerged as promising therapies, yet they differ in mechanism, outcomes, and clinical implications. The current literature lacks direct head-to-head comparisons of these two techniques regarding efficacy, long-term relief, and safety, as most studies evaluate each intervention individually. This knowledge gap, combined with the limited efficacy of conventional pharmacologic treatments, highlights the need for a comparative study to determine which approach offers superior pain relief, durability, safety, and cost-effectiveness. By examining short- and long-term outcomes, as well as resource utilization, this study aims to provide evidence-based guidance to optimize clinical decision-making, help clinicians select the most appropriate intervention for PMPS patients, and establish practical, sustainable treatment strategies. .(33, 34)

Aim of the study:

The aim of this study is to compare the effectiveness of supervoltage pulsed radifrequency of stellate ganglion and supervoltage pulsed radifrequency of T2-T3 sympathetic ganglia in the treatment of postmastectomy pain syndrome.

Primary Objectives:

To assess the degree of pain relief using Visual analogue scale (VAS scores) in 3 groups (Group S: receiving stellate ganglion supervoltage pulsed radiofrequency, Group T: receiving T2T3chains supervoltage pulsed radiofrequency as compared to Group C: Control group on tramadol 150 mg / day and gabapentin 600 mg / day) at different time intervals (baseline, 1 week, 1 month, 3 months, 6 months).

Secondary objectives:

  • To compare the dose reduction in Antineuropathic therapy.
  • To compare improvements in quality of life and sleep using (Brief pain inventory assessment tool).
  • To assess any adverse events or complications related to either procedures
  • Patient satisfaction using patient global impression of change (PGIC) Scale.

Methodology:

I. Study design:

Randomized controlled trial involves 3 Groups:

Group S receiving stellate ganglion supervoltage pulsed radiofrequency and Group T receiving T2T3chains supervoltage pulsed radiofrequency.

Group C : Control group on tramadol 150 mg / day and gabapentin 600 mg / day

II. Study setting and location:

Anesthesia and pain management Department, National Cancer Institute, Cairo University after approval by the institutional review board.

III. Study Duration: [18 months]

IV. Inclusion Criteria:

  • Female patients aged 18-60 years.
  • Patient of class II according to the American society of Anesthesiologists (ASA) physical status classification system .
  • History of unilateral mastectomy for breast cancer.
  • Persistent pain >3 months postoperatively.
  • VAS score ≥4 despite pharmacological management.
  • Patients with neuropathic pain who has a score ≥4 by Douleur Neuropathic 4 question (DN4) questionnaire. (42)
  • Patients on more than 1 antineuropathic drug.

V. Exclusion Criteria:

  • Coagulopathy or anticoagulant therapy.
  • Local infection at injection site.
  • History of psychiatric illness or cognitive dysfunction.
  • Previous intervention in the same region (e.g., prior stellate ganglion block or thoracic radiofrequency ablation).
  • Allergy to local anesthetics or contrast agents.

VI. Randomization and blinding:

This prospective, randomized, controlled trial will allocate eligible Patients into three groups in a 1:1:1 ratio using a computer-generated randomization sequence:

  • Group S : Stellate Ganglion supervoltage pulsed radiofrequency.
  • Group T : T2-T3 chains supervoltage pulsed radiofrequency.
  • Group C Control group on tramadol 150 mg / day and gabapentin 600 mg / day. Allocation concealment will be maintained with sequentially numbered, opaque, sealed envelopes prepared by an independent investigator not involved in recruitment, intervention or outcome assessment Given the nature of the interventions, patient blinding is not feasible; however, outcome assessors will remain blinded to group allocation. The interventionalist performing the procedures will not participate in follow up assessment or data collection. All statistical analysis will be conducted by statistician blinded to group assignment to minimize the bias and ensure methodological rigor.

VII. Procedure Details:

Group S - Stellate Ganglion technique:

· Super-voltage pulsed radiofrequency (PRF) of the stellate ganglion was performed under strict aseptic precautions with standard monitoring. Patients were positioned supine with a slight extension of the neck and head turned contralaterally. Ultrasound guidance using a high-frequency linear transducer was employed to identify the stellate ganglion region at the level of the C6 transverse process, anterior to the longus colli muscle and medial to the carotid sheath. A 22-gauge radiofrequency cannula (5-10 cm length, 5-mm active tip) was advanced using an in-plane technique until the needle tip was positioned adjacent to the sympathetic chain on the surface of the longus colli muscle. After negative aspiration, sensory (50 Hz) and motor (2 Hz) stimulation were performed to confirm appropriate needle placement and exclude somatic nerve involvement. Pulsed radiofrequency was then delivered using a supervoltage protocol with a pulse width of 20 ms at a frequency of 2 Hz, applying high voltage output (up to 60-65 V) while maintaining the target tissue temperature below 42°C for a total duration of 120-240 seconds. The procedure was intended to achieve neuromodulation of sympathetic fibers without thermal neurodestruction. Procedural success was assessed by the development of ipsilateral Horner's syndrome, increased upper limb temperature and subsequent decrease in pain. (35,39)

Group T- T2-T3 SUPERVOLTAGE PRF:

Position the patient prone with bolsters to minimize lordosis and allow C- arm AP and oblique imaging. Under sterile conditions use fluoroscopy to identify T2 and T3 pedicles, ribs and transverse processes. A posterior paravertebral (transforaminal-style) approach is commonly used: advance a curved RFA cannula (20-22G, 10-15 cm with 5-10 mm active tip) under fluoroscopic AP and lateral guidance to the anterolateral aspect of the vertebral body or just anterior to the costotransverse junction at the T2 and T3 levels, the expected location of the thoracic sympathetic chain. Confirm needle position with small (0.5-1 mL) contrast injection to exclude intravascular or pleural spread. Perform sensory (50 Hz) and, if applicable, motor (2 Hz) stimulation to exclude intercostal motor/pleural/nerve root proximity. For supervoltage PRF, deliver radiofrequency with pulse width 20ms at 2 Hz while maintain the electrode tip temperatue less than 42°C for 120-240 seconds at each level. Monitor for immediate complications (pneumothorax, vascular uptake, new motor deficit) and observe clinical endpoints such as ipsilateral temperature rise and pain reduction. Provide post-procedure chest imaging if pneumothorax suspected. Patient selection, careful contrast checks and stimulation testing minimize complications and improve targeting accuracy .(36,37,38)

VIII. Outcome Measures:

Primary Outcome:

Change in VAS score in groups at different time intervals (baseline, 1 week, 1 month, 3 months, 6 months).(40)

· Secondary Outcomes:

  1. Change in Brief Pain Inventory (BPI) (41) score reflecting functional improvement.
  2. dose reduction in antineuropathic drugs
  3. Patient satisfaction using patient global impression of change (PGIC)scale.42
  4. procedural complications.

IX. Follow-up Intervals:

1 week, 1 month, 3 months, 6 months post-procedure.

Tanulmány típusa

Beavatkozó

Beiratkozás (Becsült)

75

Fázis

  • Nem alkalmazható

Kapcsolatok és helyek

Ez a rész a vizsgálatot végzők elérhetőségeit, valamint a vizsgálat lefolytatásának helyére vonatkozó információkat tartalmazza.

Tanulmányi kapcsolat

Tanulmányozza a kapcsolattartók biztonsági mentését

  • Név: Salah Ismail

Tanulmányi helyek

      • Cairo, Egyiptom
        • National Cancer Institute
        • Kapcsolatba lépni:
          • National Cancer institute Cairo University
          • Telefonszám: 0225328286
          • E-mail: irb@nci.cu.edu.eg
        • Alkutató:
          • Emad Gerges, prof
        • Kutatásvezető:
          • Salah Ismail
        • Kutatásvezető:
          • Ahmed Soliman, Ass. Prof
        • Alkutató:
          • Nahla Shehab, Ass. Prof
        • Alkutató:
          • Osama Elbosraty, Lecturer

Részvételi kritériumok

A kutatók olyan embereket keresnek, akik megfelelnek egy bizonyos leírásnak, az úgynevezett jogosultsági kritériumoknak. Néhány példa ezekre a kritériumokra a személy általános egészségi állapota vagy a korábbi kezelések.

Jogosultsági kritériumok

Tanulmányozható életkorok

  • Felnőtt

Egészséges önkénteseket fogad

Nem

Leírás

Inclusion Criteria:

  • Female patients aged 18-60 years.
  • Patient of class II according to the American society of Anesthesiologists (ASA) physical status classification system.
  • History of unilateral mastectomy for breast cancer.
  • Persistent pain >3 months postoperatively.
  • VAS score ≥4 despite pharmacological management.
  • Patients with neuropathic pain who has a score ≥4 by (DN4) questionnaire.
  • Patients on more than 1 antineuropathic drug.

Exclusion Criteria:

  • Coagulopathy or anticoagulant therapy.
  • Local infection at injection site.
  • History of psychiatric illness or cognitive dysfunction.
  • Previous intervention in the same region (e.g., prior stellate ganglion block or thoracic radiofrequency ablation).
  • Allergy to local anesthetics or contrast agents.

Tanulási terv

Ez a rész a vizsgálati terv részleteit tartalmazza, beleértve a vizsgálat megtervezését és a vizsgálat mérését.

Hogyan készül a tanulmány?

Tervezési részletek

  • Elsődleges cél: Támogató gondoskodás
  • Kiosztás: Véletlenszerűsített
  • Beavatkozó modell: Párhuzamos hozzárendelés
  • Maszkolás: Négyszeres

Fegyverek és beavatkozások

Résztvevő csoport / kar
Beavatkozás / kezelés
Aktív összehasonlító: Group S: Stellate Ganglion super-voltage pulsed radiofrequency
Super-voltage pulsed radiofrequency (PRF) of the stellate ganglion was performed under strict aseptic precautions with standard monitoring. Patients were positioned supine with a slight extension of the neck and head turned contralaterally. Ultrasound guidance using a high-frequency linear transducer was employed to identify the stellate ganglion region at the level of the C6 transverse process, anterior to the longus colli muscle and medial to the carotid sheath. A 22-gauge radiofrequency cannula (5-10 cm length, 5-mm active tip) was advanced using an in-plane technique until the needle tip was positioned adjacent to the sympathetic chain on the surface of the longus colli muscle. After negative aspiration, sensory (50 Hz) and motor (2 Hz) stimulation were performed to confirm appropriate needle placement and exclude somatic nerve involvement.
· Super-voltage pulsed radiofrequency (PRF) of the stellate ganglion was performed under strict aseptic precautions with standard monitoring. Patients were positioned supine with a slight extension of the neck and head turned contralaterally. Ultrasound guidance using a high-frequency linear transducer was employed to identify the stellate ganglion region at the level of the C6 transverse process, anterior to the longus colli muscle and medial to the carotid sheath. A 22-gauge radiofrequency cannula (5-10 cm length, 5-mm active tip) was advanced using an in-plane technique until the needle tip was positioned adjacent to the sympathetic chain on the surface of the longus colli muscle. After negative aspiration, sensory (50 Hz) and motor (2 Hz) stimulation were performed to confirm appropriate needle placement and exclude somatic nerve involvement. Pulsed radiofrequency was then delivered using a supervoltage protocol with a pulse width of 20 ms at a frequency of 2 Hz, applied
Aktív összehasonlító: Group T: T2-T3 chains supervoltage pulsed radiofrequency
Position the patient prone with bolsters to minimize lordosis and allow C- arm AP and oblique imaging. Under sterile conditions use fluoroscopy to identify T2 and T3 pedicles, ribs and transverse processes. A posterior paravertebral (transforaminal-style) approach is commonly used: advance a curved RFA cannula (20-22G, 10-15 cm with 5-10 mm active tip) under fluoroscopic AP and lateral guidance to the anterolateral aspect of the vertebral body or just anterior to the costotransverse junction at the T2 and T3 levels, the expected location of the thoracic sympathetic chain. Confirm needle position with small (0.5-1 mL) contrast injection to exclude intravascular or pleural spread. Perform sensory (50 Hz) and, if applicable, motor (2 Hz) stimulation to exclude intercostal motor/pleural/nerve root proximity.
Position the patient prone with bolsters to minimize lordosis and allow C- arm AP and oblique imaging. Under sterile conditions use fluoroscopy to identify T2 and T3 pedicles, ribs and transverse processes. A posterior paravertebral (transforaminal-style) approach is commonly used: advance a curved RFA cannula (20-22G, 10-15 cm with 5-10 mm active tip) under fluoroscopic AP and lateral guidance to the anterolateral aspect of the vertebral body or just anterior to the costotransverse junction at the T2 and T3 levels, the expected location of the thoracic sympathetic chain. Confirm needle position with small (0.5-1 mL) contrast injection to exclude intravascular or pleural spread. Perform sensory (50 Hz) and, if applicable, motor (2 Hz) stimulation to exclude intercostal motor/pleural/nerve root proximity. For supervoltage PRF, deliver radiofrequency with pulse width 20ms at 2 Hz while maintain the electrode tip temperatue less than 42°C for 120-240 seconds at each level
Nincs beavatkozás: Group C: Control group on tramadol 150 mg / day and gabapentin 600 mg / day
Control group on tramadol 150 mg / day and gabapentin 600 mg / day

Mit mér a tanulmány?

Elsődleges eredményintézkedések

Eredménymérő
Intézkedés leírása
Időkeret
Change in VAS score in groups
Időkeret: 6 months
Change in visual analogue scale score in groups at different time intervals (baseline, 1 week, 1 month, 3 months, 6 months)
6 months

Másodlagos eredményintézkedések

Eredménymérő
Intézkedés leírása
Időkeret
Change in Brief Pain Inventory in groups.
Időkeret: 6 months
Change in Brief Pain Inventory (BPI) score reflecting functional improvement.
6 months
Patient satisfaction
Időkeret: 6 months
Patient satisfaction using patient global impression of change (PGIC)scale
6 months
dose reduction in antineuropathic drugs
Időkeret: 6 months
dose reduction in antineuropathic drugs
6 months
procedural complications.
Időkeret: 6 months
6 months

Együttműködők és nyomozók

Itt találhatja meg a tanulmányban érintett személyeket és szervezeteket.

Tanulmányi rekorddátumok

Ezek a dátumok nyomon követik a ClinicalTrials.gov webhelyre benyújtott vizsgálati rekordok és összefoglaló eredmények benyújtásának folyamatát. A vizsgálati feljegyzéseket és a jelentett eredményeket a Nemzeti Orvostudományi Könyvtár (NLM) felülvizsgálja, hogy megbizonyosodjon arról, hogy megfelelnek-e az adott minőség-ellenőrzési szabványoknak, mielőtt közzéteszik őket a nyilvános weboldalon.

Tanulmány főbb dátumok

Tanulmány kezdete (Becsült)

2026. július 1.

Elsődleges befejezés (Becsült)

2027. július 30.

A tanulmány befejezése (Becsült)

2027. augusztus 30.

Tanulmányi regisztráció dátumai

Először benyújtva

2026. június 23.

Először nyújtották be, amely megfelel a minőségbiztosítási kritériumoknak

2026. június 23.

Első közzététel (Tényleges)

2026. június 30.

Tanulmányi rekordok frissítései

Utolsó frissítés közzétéve (Tényleges)

2026. június 30.

Az utolsó frissítés elküldve, amely megfelel a minőségbiztosítási kritériumoknak

2026. június 23.

Utolsó ellenőrzés

2026. június 1.

Több információ

A tanulmányhoz kapcsolódó kifejezések

Terv az egyéni résztvevői adatokhoz (IPD)

Tervezi megosztani az egyéni résztvevői adatokat (IPD)?

ELDÖNTETLEN

IPD terv leírása

Till publication

Gyógyszer- és eszközinformációk, tanulmányi dokumentumok

Egy amerikai FDA által szabályozott gyógyszerkészítményt tanulmányoz

Nem

Egy amerikai FDA által szabályozott eszközterméket tanulmányoz

Nem

az Egyesült Államokban gyártott és onnan exportált termék

Nem

Ezt az információt közvetlenül a clinicaltrials.gov webhelyről szereztük be, változtatás nélkül. Ha bármilyen kérése van vizsgálati adatainak módosítására, eltávolítására vagy frissítésére, kérjük, írjon a következő címre: register@clinicaltrials.gov. Amint a változás bevezetésre kerül a clinicaltrials.gov oldalon, ez a webhelyünkön is automatikusan frissül. .

Iratkozz fel